Lv2
116 积分 2024-02-29 加入
A Patent Review on FDA-Approved Antibody-Drug Conjugates, Their Linkers and Drug Payloads
1个月前
已完结
Glucagon: the effects of its excess and deficiency on insulin action
1个月前
已完结
An overview of new GLP-1 receptor agonists for type 2 diabetes
1个月前
已完结
Emerging therapies in the treatment of ‘diabesity’: beyond GLP-1
1个月前
已完结
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
1个月前
已完结
All in one: Researchers create combination drugs for diabetes and obesity
1个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
9个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
9个月前
已完结
Dual-payload ADCs move into first oncology clinical trials
11个月前
已完结
皖公网安备34019202002308
